[Hemolysis and primaquine treatment. Preliminary report].
8 patients with paludism diagnosis due to Plasmodium vivax and deficiency of glucose-6-phosphate dehydrogenase that should receive antipaludism radical treatment with primaquine were studied. It was determined that 87.5% of the patients presented hemolysis but its relation with the enzymatic activity was not significant (p > 0.05). 50% of the patients could not finish their treatment because of the appearance of important hemolysis. It is concluded that primaquine should not be used indiscriminately among those patients with deficit of glucose 6 phosphate dehydrogenase.
Instituto de Medicina Tropical Pedro Kourí.
R
R
Menéndez Capote
L
L
Díaz Pérez
C
C
Luzardo Suárez
D000743:Anemia, Hemolytic / Q000139:chemically induced* / Q000209:etiology; D000810:Angola / Q000208:ethnology; D000962:Antimalarials / Q000009:adverse effects*; D000075202:Contraindications; D003462:Cuba / Q000453:epidemiology; D004912:Erythrocytes / Q000201:enzymology; D005954:Glucosephosphate Dehydrogenase / Q000097:blood; D005955:Glucosephosphate Dehydrogenase Deficiency / Q000097:blood / Q000150:complications* / Q000208:ethnology; D006801:Humans; D016780:Malaria, Vivax / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D011319:Primaquine / Q000009:adverse effects*; D012720:Severity of Illness Index
D000962:Antimalarials; D005954:Glucosephosphate Dehydrogenase; D011319:Primaquine